Allergic Rhinitis Rhinitis, Allergic, Perennial Quality of Life
Conditions
Interventions
Intranasal Fluticasone furoate 2 puffs each nostril once daily + Intranasal oxymetazoline 2 puffs each nostril twice daily,Intranasal Fluticasone furoate 2 puffs each nostril twice daily
Active Comparator Drug,Active Comparator Drug
Intranasal FF + Intranasal oxymetazoline ,Double dose Intranasal FF
Sponsors
Bannawat Tantikun
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1.Adults aged 18 years and older. 2.Patients diagnosed with allergic rhinitis who continue to have moderate to severe symptoms despite treatment with a standard dose of intranasal corticosteroid. 3.Willingness to participate and provide written informed consent.
Exclusion criteria
Exclusion criteria: 1.Unwillingness to participate in the study. 2.Current use of systemic corticosteroids or immunosuppressive drugs. 3.History of chronic kidney disease, liver disease, or heart disease. 4.Pregnancy or breastfeeding. 5.History of cancer or prior radiotherapy involving the head and neck region. 6.Known immunodeficiency (e.g., HIV infection). 7.History of nasal or sinus surgery. 8.Clinical evidence of acute or chronic sinusitis. 9.Presence of nasal abnormalities such as nasal polyps, tumors, septal perforation, or significant mucosal inflammation. 10.Upper respiratory tract infection within the past 14 days.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Efficacy of the intervention 2 weeks Thai Rhinoconjunctivitis Quality of Life Questionnaire; RCQ36 | — |
Secondary
| Measure | Time frame |
|---|---|
| Onset of action 2 weeks Time(day) of which VAS scale significantly different from the baseline,Safety outcome 2 weeks frequency (%) of rhinitis medicamentosa in oxymetazoline + intranasal FF arm | — |
Countries
Thailand
Contacts
Public ContactBannawat Tantikun
Faculty of Medicine Vajira Hospital, Navamindradhiraj University
Outcome results
None listed